What new gene-editing technology, known as Dualase®, designed to enhance CRISPR's accuracy, received new funding in March 2026?

A significant advancement in gene-editing technology, known as Dualase®, is making waves, specifically as a dual-cleaving nuclease. This innovative tool is designed to enhance the precision of CRISPR, a groundbreaking gene-editing system. In March 2026, the technology received new funding, underscoring its potential to revolutionize the treatment of genetic diseases.

Unlike traditional gene editors that typically make a single cut in DNA, Dualase® employs a unique mechanism that creates two targeted cuts. This dual-cutting strategy is crucial because it helps cells repair themselves with greater accuracy, significantly reducing the risk of unintended genetic alterations. Researchers involved in its development highlight that while first-generation editors are adept at breaking genes, Dualase® aims to restore the correct genetic sequence, offering a more refined approach to gene therapy.

The recent investment, totaling over CAD $1.8 million from Genome Canada and Ontario Genomics, will accelerate the development of Dualase® through a machine-learning platform. This platform will help predict optimal editor designs, compressing development timelines and speeding up the path to new therapies. The implications are substantial, with Dualase® already being explored for conditions like amyotrophic lateral sclerosis (ALS) and Huntington's disease, offering hope for correcting underlying mutations in diseases with limited treatment options.